SCHEMBL6510105

SCHEMBL6510105

Cc1cccc(C(C=O)c2ccncc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.44
CYP19A1 P11511 2/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
KMT2A Q03164 2/20 0.40
PKM P14618 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.39
NT5E P21589 1/20 0.39
ACP3 P15309 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
GAA P10253 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNK3 O14649 1/20 0.36
KCNK9 Q9NPC2 1/20 0.36
ACHE P22303 1/20 0.35
ROCK2 O75116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9729373 0.88 ACHE (0.46) CYP19A1ACP3NPC1GAAACHE
SCHEMBL1515743 0.86 ACP3 (0.50) SMN1; SMN2ACP3GAAACHE
SCHEMBL6499767 0.84 CYP3A4 (0.35) MAPKAPK2CYP19A1CYP11B1CYP11B2KMT2A
SCHEMBL6499586 0.84 PSEN1 (0.44) MAPKAPK2CYP19A1CYP11B1CYP11B2ACP3
SCHEMBL3903975 0.84 CYP11B1 (0.44) MAPKAPK2CYP19A1CYP11B1SMN1; SMN2NPC1
SCHEMBL6504970 0.80 CYP19A1 (0.39) CYP19A1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3907301 0.80 CYP19A1 (0.41) CYP19A1CYP11B1CYP11B2KMT2ASMN1; SMN2
SCHEMBL3403146 0.80 CYP11B1 (0.41) CYP19A1CYP11B1CYP11B2SLC6A2SLC6A4
SCHEMBL2145850 0.80 ALDH1A1 (0.39) KMT2ANPC1RAB9ASLC6A2SLC6A4
SCHEMBL1515763 0.80 SLC6A3 (0.58) KMT2AMEN1GAASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 MAPKAPK2 14/4885CYP19A1 2827/4885CYP11B1 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.